Current Strategies in the Treatment of HIV Infection

Advances in Internal Medicine

Volumn 46, Issue , 2001, Pages 207-246

  Cohen, Oren J ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035219324     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Pantaleo G, Graziosi C, Demarest JF, et al: HTV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358, 1993.
2. Embretson J, Zupancic M, Ribas J, et al: Massive covert infection of helper T lymphocytes and macrophages by HTV during the incubation period of AIDS. Nature 362:359-362, 1993.
3. Ho DD, Neumann AU, Perelson AS, et al: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126, 1995.
4. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122, 1995.
5. Perelson AS, Neumann AU, Markowitz M, et al: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586, 1996.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. AT Engl J Med 338:853-860, 1998.
7. Mocroft A, Vella S, Benfield TL, et al: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352:1725-1730, 1998.
8. Vittinghoff E, Scheer S, O'Malley P, et al: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. / Infect Dis 179:717-720, 1999.
9. Detels R, Munoz A, McFarlane G, et al: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HTV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280:1497-1503, 1998.
10. Locati M, Murphy PM: Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS. Annu Rev Med 50:425-440, 1999.
11. Sodroski JG: HIV-1 entry inhibitors in the side pocket. Cell 99:243246, 1999.
12. Bukrinsky MI, Sharova N, Dempsey MP, et al: Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sei USA 89:6580-6584, 1992.
13. Schooley R, Merigan T, Gaut P, et al: Recombinant soluble CD4 therapy in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 112:247-253, 1990.
14. Baggiolini M, Moser B: Blocking chemokine receptors. / Exp Med 186:1189-1191, 1997.
15. Kilby JM, Hopkins S, Venetta TM, et al: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302-1307, 1998.
16. Navia MA, Fitzgerald PM, McKeever BM, et al: Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615-620, 1989.
17. Wlodawer A, Miller M, Jaskolski M, et al: Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245:616-621, 1989.
18. Dyda F, Hickman AB, Jenkins TM, et al: Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 266:1981-1986, 1994.
19. Haubrich RH, Flexner C, Lederman MM, et al: A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. / Infect Dis 172:1246-1252, 1995.
20. Perelson AS, Essunger P, Cao Y, et al: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387:188191, 1997.
21. Mellors JW, Rinaldo CR, Gupta P, et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170, 1996.
22. O'Brien WA, Hartigan PM, Martin D, et al: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N EngI J Med 334:426-431, 1996.
23. Staszewski S, Miller V, Sabin C, et al: Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 13:951-956, 1999.
24. Miller V, Staszewski S, Sabin C, et al: CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. / Infect Dis 180:530-533, 1999.
25. Autran B, Carcelain G, Li T, et al: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997.
26. Pakker NG, Notermans DW, de Boer RJ, et al: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 4:208-214, 1998.
27. Gorochov G, Neumann AU, Kereveur A, et al: Perturbation of CD4+ and CDS+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 4:215221,1998.
28. McCune JM, Loftus R, Schmidt DK, et al: High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. / Clin Invest 101:2301-2308, 1998.
29. Douek DC, McFarland RD, Keiser PH, et al: Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690-695, 1998.
30. Komanduri KV, Viswanathan MN, Wieder ED, et al: Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953-956, 1998.
31. Schneider MM, Borleffs JC, Stolk RP, et al: Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353:201-203, 1999.
32. Weverling GJ, Mocroft A, Ledergerber B, et al: Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 353:1293-1298, 1999.
33. Furrer H, Egger M, Opravil M, et al: Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. NEnglJMed 340:1301-1306, 1999.
34. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 48:1-67, 1999.
35. Yarchoan R, Weinhold K, Lyerly H, et al: Administration of 3'-azido3'-deoxythymidine, an inhibitor of HTLV-IÜ/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1:8481:575-580,1986.
36. Fischl M, Richman D, Grieco M, et al: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. NEnglJMed 317:185191, 1987.
37. Fischl M, Richman D, Hansen N, et al: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type l (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 112:727-737,1990.
38. Volberding P, Lagakos S, Koch M, et al: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. NEnglJMed 322:941-949, 1990.
39. Volberding P, Lagakos S, Grimes J, et al: The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 272:437442, 1994.
40. Collier AC, Coombs RW, Fischl MA, et al: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV1 infection. Ann Intern Med 119:786-793, 1993.
41. Hammer SM, Katzenstein DA, Hughes MD, et al: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335:1081-1090, 1996.
42. Graham NMH, Hoover DR, Park LP, et al: Survival in HIV-infected patients who have received zidovudine: Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 124:1031-1038, 1996.
43. Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348:283-291, 1996.
44. Eron JJ, Benoit SL, Jemsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV working party. N Engl J Med 333:1662-1669, 1995.
45. Department of Health and Human Services/Henry J. Kaiser Family Foundation Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Current guidelines available at www.hivatis.org. Ann Intern Med 128:1079-1100, 1998.
46. Mellors JW, Munoz A, Giorgi JV, et al: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946-954, 1997.
47. Gulick R, Mellors J, Havlir D, et al: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739, 1997.
48. Hammer S, Squires K, Hughes M, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725-733, 1997.
49. Cameron DW, Heath-Chiozzi M, Danner S, et al: Randomised placebocontrolled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351:543-549,1998.
50. Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 131:81-87, 1999.
51. Hsu A, Granneman GR, Cao G, et al: Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464, 1998.
52. Cameron DW, Japour AJ, Xu Y, et al: Ritonavir and saquinavir combination therapy for the treatment of HTV infection. AIDS 13:213-224,1999.
53. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al: The steadystate plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1infected individuals. AIDS 13:F95-F99, 1999.
54. Kempf DJ, Marsh KG, Kumar G, et al: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654660, 1997.
55. Staszewski S, Morales-Ramirez J, et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl JMed 341:1865-1873, 1999.
56. Staszewski S, Keiser P, Gathe J, et al: Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapynaive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract 505, 1999.
57. Deeks SG, Hecht FM, Swanson M, et al: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 13:F35-F43,1999.
58. Devereux I-IL, Youle M, Johnson MA, et al: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:123-127, 1999.
59. Durant J, Clevenbergh P, Halfon P, et al: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353:2195-2199, 1999.
60. Baxter JD, Mayers DL, Wentworth DN, et al: CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections Abstract LB8, 1999.
61. Hecht FM, Grant RM, Petropoulos CJ, et al: Sexual transmission of an HFV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl f Med 339:307-311, 1998.
62. Yerly S, Kaiser L, Race E, et al: Transmission of antiretroviral-drugresistant HIV-1 variant. Lancet 354:729-733, 1999.
63. Boden D, Hurley A, Zhang L, et al: HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141, 1999.
64. Little SJ, Daar ES, D'Aquila RT, et al: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149, 1999.
65. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl JMed 333:408-413, 1995.
66. Lillo FB, Ciuffreda D, Veglia F, et al: Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 13:791-796, 1999.
67. Hoen B, Dumon B, Harzic M, et al: Highly active antiretroviral treat-ment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial. / Infect Dis 180:1342-1346, 1999.
68. Havlir D, Hellmann N, Petropoulos C, et al: Viral rebound in the presence of indinavir without protease inhibitor resistance. JAMA, in press, 2000.
69. Gulick RM, Mellors JW, Havlir D, et al: Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 280:35-41, 1998.
70. Ledergerber B, Egger M, Opravil M, et al: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 353:863-868, 1999.
71. Powderly WG, Saag MS, Chapman S, et al: Predictors of optimal virological response to potent antiretroviral therapy. AIDS 13:1873-1880, 1999.
72. Acosta EP, Henry K, Baken L, et al: Indinavir concentrations and antiviral effect. Pharmacothempy 19:708-712, 1999.
73. Montaner JS, Reiss P, Cooper D, et al: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INGAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279:930-937, 1998.
74. Paterson D, Swindells S, Mohr J, et al: How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps. 6th Conference on Retroviruses and Opportunistic Infections Abstract 92, 1999.
75. Brinkman K, ter Hofstede HJ, Burger DM, et al: Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway (editorial). AIDS 12:1735-1744, 1998.
76. Walli R, Herfort O, Michl GM, et al: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12:F167-173, 1998.
77. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58, 1998.
78. Carr A, Samaras K, Thorisdottir A, et al: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 353:2093-2099, 1999.
79. Cart A, Samaras K, Chisholm DJ, et al: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883, 1998.
80. Brinkman K, Smeitink JA, Romijn JA, et al: Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy (comment). Lancet 354:1112-1115, 1999.
81. Larder B, Kemp S: Multiple mutations in I-[IV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:11551158, 1989.
82. Winters MA, Schapiro JM, Lawrence J, et al: Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. / Virol 72:5303-5306, 1998.
83. Schapiro JM, Winters MA, Lawrence J, et al: Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 13:359-365, 1999.
84. Zhang YM, Imamichi H, Imamichi T, et al: Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. / Virol 71:6662-6670, 1997.
85. Piketty C, Race E, Castiel P, et al: Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 13:F71-F77, 1999.
86. Parkin NT, Lie YS, Hellmann N, et al: Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy, J Infect Dis 180:865870, 1999.
87. Chun TW, Stuyver L, Mizell SB, et al: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc NatI Acad Sei U S A 94:13193-13197, 1997.
88. Natarajan V, Bosche M, Metcalf JA, et al: HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 353:119-120, 1999.
89. Furtado MR, Callaway DS, Phair JP, et al: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. NEnglJMed 340:1614-1622, 1999.
90. Dornadula G, Zhang H, VanUitert B, et al: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627-1632,1999.
91. Martinez MA, Cabana M, Ibanez A, et al: Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256:180-187, 1999.
92. Zhang L, Ramratnam B, Tenner-Racz K, et al: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. NEnglJMed 340:1605-1613, 1999.
93. Harrigan PR, Whaley M, Montaner JS: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13:F59-F62, 1999.
94. Garcia F, Plana M, Vidai C, et al: Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13:F79-F86, 1999.
95. Davey RT, Jr, Bhat N, Yoder C, et al: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sei USA 96:15109-15114, 1999.
96. Stein DS, Fish DG, Bilello JA, et al: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492, 1996.
97. Eron JJ, Vernazza PL, Johnston DM, et al: Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission. AIDS 12:F181-F189, 1998.
98. Zhang H, Dornadula G, Beumont M, et al: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. NEnglJMed 339:1803-1809, 1998.
99. Wolthers KG, Wisman GBA, Otto SA, et al: T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover. Science 274:1543-1547, 1996.
100. Palmer LD, Weng N, Levine BL, et al: Telomere length, telomerase activity, and replicative potential in HIV infection: Analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. /Exp Med 185:1381-1386, 1997.
101. Lempicki R, Kovacs J, Baseler M, et al: Impact of therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients receiving highly active antiretroviral therapy or interleukin-2, Proc Natl Acad Sei USA, 2000, in press.
102. Sachsenberg N, Perelson AS, Yerly S, et al: Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. JExp Med 187:1295-1303, 1998.
103. Fleury S, de Boer RJ, Rizzardi GP, et al: Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. Nat Med 4:794-801, 1998.
104. Hellerstein M, Hanley MB, César D, et al: Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 5:83-89, 1999.
105. Bucy RP, Hockett RD, Derdeyn ÇA, et al: Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues, / din Invest 103:1391-1398, 1999.
106. Walker RE, Carter CS, Muul L, et al: Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 4:852-856, 1998.
107. Haynes BF, Hale LP, Weinhold KJ, et al: Analysis of the adult thymus in reconstitution of T lymphocytes in HIV- 1 infection, / Clin Invest 103:453-460, 1999.
108. Zhang L, Lewin SR, Markowitz M, et al: Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. JExp Med 190:725-732,1999.
109. Zhang ZQ, Schuler T, Cavert W, et al: Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sei USA 96:5169-5172, 1999.
110. Orenstein JM, Feinberg M, Yoder C, et al: Lymph node architecture preceding and following potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen. Restoration after lymph node involution and CD4 cell depletion in an AIDS patient. AIDS 13:2219-2229, 1999.
111. Hengel RL, Jones BM, Kennedy MS, et al: Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naïve T cells following triple-drug therapy for MV type 1 infection. AIDS Res Hum Retrovimses 15:435-443,1999.
112. Li TS, Tubiana R, Katlama C, et al: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351:1682-1686, 1998.
113. Rinaldo Jr CR, Liebmann JM, et al: Prolonged suppression of human immunodeficiency virus type 1 (HTV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. /Infect Dis 179:329-336, 1999.
114. Zauli G, Capitani S: HIV-1-related mechanisms of suppression of CD34+ hematopoietic progenitors. Pathobiology 64:53-58, 1996.
115. Dybul M, Kinter A, Ruiz M, et al: Promethean thymus? / Clin Invest 101:2299-2300, 1998.
116. Kovacs JA, Vogel S, Albert JM, et al: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. NEnglJMed 335:1350-1356, 1996.
117. Rosenberg ES, Billingsley JM, Caliendo AM, et al: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450, 1997.
118. Borrow P, Lewicki H, Hahn BH, et al: Virus-specific CD8+ cytotoxic Tlymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. / Virol 168:61036110, 1994.
119. Koup RA, Safrit JT, Cao Y, et al: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. / Virol 68:4650-4655,1994.
120. Musey L, Hughes J, Schacker T, et al: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. NEnglJMed 337:1267-1274, 1997.
121. Pantaleo G, Menzo S, Vaccarezza M, et al: Studies in subject with long-term nonprogressive human immunodeficiency virus infection. NEnglJMed 332:209-216, 1995.
122. Klein MR, vanBaalen CA, Holwerda AM, et al: Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. JExp Med 181:1365-1372, 1995.
123. Rinaldo C, Huang X-L, et al: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. / Virol 69:5838-5842, 1995.
124. Walker BD, Chakrabarti S, Moss B, et al: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-348, 1987.
125. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, et al: Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. JImmunol 142:452-462, 1989.
126. Ogg G, Jin X, Bonhoeffer S, et al: Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:21032106, 1998.
127. Rowland-Jones S, Sutton J, Ariyoshi K, et al: HIV-specific cytotoxic Tcells in HIV-exposed but uninfected Gambian women. Nat Med 1:5964, 1995.
128. Rowland-Jones SL, Dong T, Fowke KR, et al: Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV- resistant prostitutes in Nairobi. / Clin Invest 102:1758-1765, 1998.
129. Tenner-Racz K, Racz P, Thome C, et al: Cytotoxic effector cell granules recognized by the monoclonal antibody TIA-1 are present in CD8+ lymphocytes in lymph nodes of human immunodeficiency virus-1infected patients. AmJPathol 142:1750-1758, 1993.
130. Schmitz JE, Kuroda MJ, Santra S, et al: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860, 1999.
131. Matano T, Shibata R, Siemon C, et al: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. / Virol 72:164-169, 1998.
132. Jin X, Bauer DE, Tuttleton SE, et al: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virusinfected macaques. J Exp Med 189:991-998, 1999.
133. Pitcher CJ, Quittner C, Peterson DM, et al: HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV- l infection, but decline with prolonged viral suppression. Nat Med 5:518-525, 1999.
134. Markowitz M, Vesanen M, Tenner-Racz K, et al: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. / Infect Dis 179:527-537, 1999.
135. Gray CM, Lawrence J, Schapiro JM, et al: Frequency of class I HLArestricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). JImmunol 162:1780-1788,1999.
136. Kalams SA, Goulder PJ, Shea AK, et al: Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. / Virol 73:6721-6728, 1999.
137. Ogg GS, Jin X, Bonhoeffer S, et al: Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. / Virol 73:797-800, 1999.
138. Ortiz GM, Nixon DF, Trkola A, et al: HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. / Clin Invest 104:R13-R18, 1999.
139. Zack JA, Arrigo SJ, Weitsman SR, et al: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61:213-222, 1990.
140. Stevenson M, Stanwick TL, Dempsey MP, et al: HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J 9:1551-1560, 1990.
141. Bukrinsky M, Stanwick T, Dempsey M, et al: Quiescent T lymphocytes as an inducible vires reservoir in HTV-1 infection. Science 254:423-427, 1991.
142. Chun TW, Finzi D, Margolick J, et al: In vivo fate of HTV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1:1284-1290, 1995.
143. Chun T-W, Carruth L, Finzi D, et al: Quantification of latent tissue reservoirs and total body viral load in HIV infection. Nature 387:183187, 1997.
144. Finzi D, Hermankova M, Pierson T, et al: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300, 1997.
145. Wong JK, Hezareh M, Gunthard HF, et al: Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295, 1997.
146. Finzi D, Blankson J, Siliciano ID, et al: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517,1999.
147. Ramratnam B, Mittler YE, Zhang L, et al: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82-85, 2000.
148. Chun TW, Engel D, Mizell SB, et al: Induction of HIV-1 replication in latently infected CD4(+) T cells using a combination of cytokines. JExp Med 188:83-91, 1998.
149. Chun TW, Engel D, Mizell SB, et al: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 5:651-655, 1999.
150. Chun T-W, Davey RTJ, Engel D, et al: Re-emergence of HIV after stopping therapy. Nature 401:874-875,1999.
151. Chun T-W, Fauci AS: Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sei USA 96:10958-10961, 1999.
152. Schräger LK, D'Souza MP: Cellular and anatomical reservoirs of HIV1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71, 1998.